ImmunoACT Revenue and Competitors
Estimated Revenue & Valuation
- ImmunoACT's estimated annual revenue is currently $27.7M per year.
- ImmunoACT's estimated revenue per employee is $155,000
Employee Data
- ImmunoACT has 179 Employees.
- ImmunoACT grew their employee count by 46% last year.
ImmunoACT's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder | Reveal Email/Phone |
2 | Assistant Manager | Reveal Email/Phone |
3 | Project Manager | Reveal Email/Phone |
4 | Assistant Manager | Reveal Email/Phone |
5 | Project Manager | Reveal Email/Phone |
6 | Finance Manager | Reveal Email/Phone |
7 | Assistant Manager (Facility & Operations) | Reveal Email/Phone |
8 | Scientist-III | Reveal Email/Phone |
9 | Principal Scientist | Reveal Email/Phone |
10 | Quality Assurance Executive | Reveal Email/Phone |
ImmunoACT Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $92.2M | 595 | 72% | N/A | N/A |
#2 | $90.4M | 583 | 30% | N/A | N/A |
#3 | $1.4M | 9 | 80% | N/A | N/A |
#4 | $27.7M | 179 | 46% | N/A | N/A |
#5 | $2.6M | 17 | 13% | N/A | N/A |
#6 | $2M | 13 | 8% | N/A | N/A |
#7 | $22.6M | 120 | 90% | $16.6M | N/A |
#8 | $4.5M | 24 | 14% | N/A | N/A |
What Is ImmunoACT?
Spun-out from IIT-Bombay in 2018, ImmunoACT is India's pioneer of Gene-modified Cell Therapies, having launched the country's first CAR-T cell therapy for treatment of certain B-cell malignancies. With a rapidly expanding pipeline beginning, our mission is to provide affordable access to novel CAR-T cell therapies.
keywords:N/AN/A
Total Funding
179
Number of Employees
$27.7M
Revenue (est)
46%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $19.8M | 180 | -4% | N/A |
#2 | $28.9M | 181 | 4% | N/A |
#3 | $21.1M | 192 | 14% | N/A |
#4 | $45.5M | 197 | 25% | N/A |
#5 | $23.3M | 212 | 6% | N/A |